Multi User License - $2,500
Smart inhalers use Bluetooth technology to track inhaler usage, remind patients to take their prescription, and collect data to aid in care planning.
When a patient enters a high pollen or extremely polluted area, the device sends a smartphone alert, allowing the patient to select whether or not to enter the area. Smart inhalers include sensors that allow patients to automatically track how often they use their inhaler, eliminating the possibility of human error.
The North America Smart Inhalers Market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2026, registering a CAGR of XX% from 2022 to 2027.
BreatheSuite Inc., a Canadian connected respiratory health startup, announced that their BreatheSuite Metered-Dose Inhaler (MDI) V1 device has been cleared by the US Food and Drug Administration (FDA). The BreatheSuite gadget converts existing MDIs into smart inhalers by automatically and objectively monitoring and delivering feedback on inhaler adherence and technique for persons with asthma and COPD. It is approved for both prescription and over-the-counter use.
Teva Pharmaceuticals announced the U.S. launch of its ProAir Digihaler. Teva ProAir Inhaler is working on a line of smart digital inhalers that connect to applications, which will improve on the first-generation medicine-only dispenser shown. Teva’s ArmonAir Digihaler monotherapy maintenance medication, which was just approved, completes the Digihaler product line. The Pro-Air Digihaler for rescue treatment and the AirDuo Digihaler for combined maintenance are the two previous Teva approvals. Teva Pharmaceutical now has three smart inhalers.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.